尖峰集团：子公司尖峰药业获得恩格列净化学原料药上市申请批准通知书

Core Viewpoint - Jianfeng Group's subsidiary, Jianfeng Pharmaceutical, has received approval from the National Medical Products Administration for the marketing of the chemical raw material drug, Empagliflozin, which meets national technical standards for raw material drug review and can now be sold in the domestic market, aiding in business expansion [1] Summary by Categories Company Developments - Jianfeng Pharmaceutical has been granted a marketing approval for Empagliflozin, indicating a significant step in expanding its product offerings [1] Industry Context - The approval of Empagliflozin aligns with the high-tech, high-risk, and high-value characteristics of pharmaceutical products, which are subject to fluctuations due to national policies and market environment changes, highlighting the inherent uncertainties in the industry [1]